CytoMed Therapeutics Limited
FRC CoverageCytoMed Therapeutics Limited
FRC CoverageYour view on GDTC
Overview
What the company does, where it operates, and who runs it.
*CytoMed Therapeutics Limited has paid FRC a fee for research coverage and distribution of reports.
About CytoMed Therapeutics Limited
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Chee Kong Choo
- Headquarters
- 1 Commonwealth Lane, No. 08-22, Singapore, SG
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Chee Kong Choo
- Headquarters
- 1 Commonwealth Lane, No. 08-22, Singapore, SG
CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers.
The company's lead product candidate is CTM-N2D, which consists of expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor to improve anti-cancer cytotoxicity.
It is also developing iPSC-gdNKT, which utilizes iPSC as a starting material to generate gdNKT, a synthetic hybrid of a gamma delta T cell and a NK cell; and CTM-GDT, a product candidate that consists of expanded gamma delta T cells, and exploits the multiple recognition system of gamma delta T cell to recognize and treat a range of cancers.
The company was incorporated in 2018 and is headquartered in Singapore.
Research Reports
FRC analyst coverage and recommendations.
Past Reports
Historical coverage archive.
Analyst Notes
Ongoing commentary and updates from FRC analysts.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for CytoMed Therapeutics Limited, and the rating behind it. GDTC last traded at $0.78; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for CytoMed Therapeutics Limited. Starting points for CytoMed Therapeutics Limited: EPS -$0.41, beta 0.05 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for CytoMed Therapeutics Limited. CytoMed Therapeutics Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for CytoMed Therapeutics Limited. Trailing twelve-month EPS for CytoMed Therapeutics Limited stands at -$0.41. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for CytoMed Therapeutics Limited. CytoMed Therapeutics Limited has reported as a listed company since 2023. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
CytoMed Therapeutics Limited valued side by side against its closest peers. CytoMed Therapeutics Limited is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold CytoMed Therapeutics Limited, and how their positions are changing. At a $9.3M market value, institutional positions materially move CytoMed Therapeutics Limited's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by CytoMed Therapeutics Limited executives and directors. Shares of CytoMed Therapeutics Limited have traded between $1.65 and $4.05 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming CytoMed Therapeutics Limited. CytoMed Therapeutics Limited is a $9.3M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming CytoMed Therapeutics Limited. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for CytoMed Therapeutics Limited. Coverage tracks CytoMed Therapeutics Limited within Biotechnology (Healthcare). Press releases and market coverage, newest first.
